{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Vaccines&page=6",
    "query": {
      "condition": "COVID-19 Vaccines",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 327,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Vaccines&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=COVID-19+Vaccines&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T02:06:22.939Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05543642",
      "title": "The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatic Diseases"
      ],
      "interventions": [
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphtheria, pertussis, and tetanus booster vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 129,
      "start_date": "2022-10-11",
      "completion_date": "2026-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 7,
      "location_summary": "Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Riverview",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Clovis",
          "state": "New Mexico"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543642"
    },
    {
      "nct_id": "NCT05477186",
      "title": "Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "CV0501 (3 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (6 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (12 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (25 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (50 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (100 μg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CV0501 (200 μg)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2022-08-12",
      "completion_date": "2023-08-18",
      "has_results": true,
      "last_update_posted_date": "2025-02-21",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05477186"
    },
    {
      "nct_id": "NCT05543616",
      "title": "A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Virus",
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Months to 11 Years"
      },
      "enrollment_count": 4338,
      "start_date": "2022-09-23",
      "completion_date": "2026-07-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05543616"
    },
    {
      "nct_id": "NCT05397223",
      "title": "A Study of Modified mRNA Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS-CoV-2",
        "Seasonal Influenza",
        "Respiratory Syncytial Virus",
        "Cytomegalovirus"
      ],
      "interventions": [
        {
          "name": "mRNA-1273",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1010",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLUAD®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mRNA-1647",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 308,
      "start_date": "2022-05-24",
      "completion_date": "2026-02-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 8,
      "location_summary": "Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397223"
    },
    {
      "nct_id": "NCT04336410",
      "title": "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Coronavirus Infection"
      ],
      "interventions": [
        {
          "name": "INO-4800",
          "type": "DRUG"
        },
        {
          "name": "CELLECTRA® 2000",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Inovio Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-04-03",
      "completion_date": "2022-02-10",
      "has_results": false,
      "last_update_posted_date": "2022-04-15",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 3,
      "location_summary": "Lexington, Kentucky • Kansas City, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04336410"
    },
    {
      "nct_id": "NCT05084976",
      "title": "Parental Perception of COVID-19 Vaccine in Technology Dependent Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Respiratory Failure",
        "Tracheostomy Complication",
        "Mechanical Ventilation Complication"
      ],
      "interventions": [
        {
          "name": "COVID 19 vaccine counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-09-23",
      "completion_date": "2022-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-07-18",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 1,
      "location_summary": "Lake Success, New York",
      "locations": [
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05084976"
    },
    {
      "nct_id": "NCT04895189",
      "title": "Yale COVID-19 Recovery Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Covid19 Sequelae"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-05-03",
      "completion_date": "2025-05-09",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04895189"
    },
    {
      "nct_id": "NCT05997290",
      "title": "A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "SARS-CoV-2 Infection",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "BNT162b2 (Omi XBB.1.5)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (Omi JN.1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT162b2 (Omi KP.2)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1051,
      "start_date": "2023-08-10",
      "completion_date": "2025-03-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 37,
      "location_summary": "Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997290"
    },
    {
      "nct_id": "NCT06020118",
      "title": "Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sequential Vaccination (Influenza vaccine then mRNA COVID booster)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sequential Vaccination (mRNA COVID booster then Influenza vaccine)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "6 Years to 64 Years"
      },
      "enrollment_count": 455,
      "start_date": "2023-09-25",
      "completion_date": "2024-05-17",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06020118"
    },
    {
      "nct_id": "NCT04505774",
      "title": "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "theraputic heparin",
          "type": "DRUG"
        },
        {
          "name": "prophylactic heparin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12",
          "type": "DRUG"
        },
        {
          "name": "Crizanlizumab Injection",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Matthew Neal MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3591,
      "start_date": "2020-09-04",
      "completion_date": "2024-01-26",
      "has_results": true,
      "last_update_posted_date": "2024-12-30",
      "last_synced_at": "2026-10-07T02:06:22.939Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fontana",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04505774"
    }
  ]
}